Role of Ischemia Modified Albumin in the early diagnosis of Acute Coronary Syndromes

Abstract

The diagnosis of ACS is missed in approximately 2% of patients, leading to substantial consequences. So differentiating ACS from non cardiac chest pain is the primary diagnostic challenge. There is a desperate need for an early and sensitive marker for detection of cardiac ischemia in order to save the myocardium from necrosis. Measurement of ischemia modified albumin is based on the premise that oxidative stress conditions such as myocardial ischemia release free oxygen radicals which lead to reduction in the binding capacity of human serum albumin to transitional metals particularly cobalt. Our study aimed to evaluate the role of serum ischemia modified albumin as an early marker for diagnosis of acute coronary syndrome in patients presenting with acute chest pain. Our study included 200 patients, with ACS who arrived at the ED within 3 hour from onset of chest pain. The patients were diagnosed and classified as (STEMI, NSTEMI, UA or non cardiac chest pain), depending upon the assessment of clinical signs & symptoms, serial 12-lead ECG and cardiac biomarkers.